MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: New gene to predict outcome in pancreatic cancer

Back to pancreas Blogs list Cancer blog  


Subscribe To Pancreas RSS Feed  RSS content feed What is RSS feed?

New gene to predict outcome in pancreatic cancer




Variations in mismatch repair genes can help predict therapy response and prognosis in patients with pancreas cancer, as per research from The University of Texas M. D. Anderson Cancer Center presented today in advance of the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

In the study, single nucleotide polymorphisms (SNPs) in genes involved in DNA mismatch repair were linked to response to gemcitabine (Gemzar)-based preoperative chemoradiation, tumor resectability (the likelihood of removing the entire tumor), and overall survival.



New gene to predict outcome in pancreatic cancer

"Gemcitabine is a major chemotherapeutic agent used to treat pancreas cancer, but we don't understand why some patients respond and most patients do not," said Donghui Li, Ph.D., the study's main author and professor in M. D. Anderson's Department of Gastrointestinal Medical Oncology. "There has been no biomarker for pancreas cancer used in the clinic to predict response. Our research interest has been to determine whether genetic variation in DNA repair can be a predictor of therapy response or a prognosis factor for patient survival".

DNA repair is a complicated process, Li noted, with various mechanisms responsible for identifying and correcting different types of DNA damage. Mismatch repair genes correct mistakes in DNA replication or trigger cell death (apoptosis) if repair is not possible. Ensuring cell death is critical to preventing the runaway cell division that occurs in cancerous tumors.

In the study, Li's group obtained DNA samples from 154 patients with potentially resectable pancreatic adenocarcinomas who were participating in phase II clinical trials of preoperative gemcitabine-based chemoradiation. The scientists reviewed 15 SNPs (also called genotypes) among eight mismatch repair genes (EXO1, MLH1, MSH2, MSH3, MSH6, PMS1, TREX1, and TP73) and correlated them with tumor response to gemcitabine, the likelihood of achieving complete tumor resection, and overall survival.

Individually, five genotypes were linked to tumor response to preoperative gemcitabine-based chemoradiation; six were linked to tumor resectability, and ten were linked to overall survival. However, the combined effects of several genotypes on patient survival were dramatic. For example, 20 of 25 patients with 0 to 1 abnormal genotype were alive at the completion of the study (after a median follow-up time of 49.9 months). In contrast, median survival times were 36.2 months for patients with 2 adverse genotypes; 23.9 months for those with 3; 16.3 months for those with 4; 13 months for those with 5; and 8.3 months for those with 6 - 7.

If confirmed by other researchers, these findings could have a profound effect on how pancreas cancer is treated. Having established biomarkers like abnormal mismatch repair genes, for example, would make choosing which patients might benefit from surgery much easier, Li explained.

"The doctor always faces a tough choice," Li said. "Among the pancreatic tumors that are technically respectable, 25-30 percent might have very small tumors that have already metastasized to the liver or other organs. For these patients, the tumors recur very shortly after surgery, so these patients actually do not benefit from the traumatic and difficult surgery."

The study results also suggest that variations in mismatch repair genes could be useful in determining which patients will respond best to gemcitabine-based chemoradiation. Having this information would allow physicians to move more quickly to give alternative drugs to a patient unlikely to respond to gemcitabine, Li explained.

"We hope that in the future we will be able to run a genetic test that will help doctors predict a patient's outcome and help them select the best treatment for each patient," Li concluded.


Posted by: Sue    Source




Did you know?
Variations in mismatch repair genes can help predict therapy response and prognosis in patients with pancreas cancer, as per research from The University of Texas M. D. Anderson Cancer Center presented today in advance of the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

Medicineworld.org: New gene to predict outcome in pancreatic cancer

Advances in pancreatic cancer treatment| Detailed information on pancreatic cancer| Pancreas cancer main| Major topics in pancreatic cancer| Overview of pancreatic cancer| Pancreatic cancer resources| More resources for pancreatic cancer| Resources 3 for pancreatic cancer| Resources4 for pancreatic cancer| Resources5 for pancreatic cancer| Resources6 for pancreatic cancer| Resources7 for pancreatic cancer| Resources8 for pancreatic cancer|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.